Education
About Us
Working with TipRanks
Follow Us
Annexon Biosciences (ANNX)
NASDAQ:ANNX
ANNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.29 - $7.85
Previous CloseN/A
Volume252.73K
Average Volume (3M)2.11M
Market Cap
$350.54M
Enterprise Value$156.58M
Total Cash (Recent Filing)$227.02M
Total Debt (Recent Filing)$27.63M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Nov 12, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding109,886,620
10 Day Avg. Volume2,691,866
30 Day Avg. Volume2,106,034
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue46.00
Enterprise Value/Gross Profit-160.43
Enterprise Value/Ebitda-0.79
Forecast
1Y Price Target
$11.60Price Target Upside263.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEarly completion of Phase 3 enrollment for the vonaprument (ANX007) program and entry into EMA’s PRIME PDC pilot increase the credibility of the 'vision preservation' label ambition.
Financial StabilityThe 2Q25 cash balance of $227M is sufficient into 2H26.
Regulatory ApprovalThe EU-first pivot with an MAA in Q1 2026 is considered de-risked due to EMA's familiarity and prior deep dive.
Therapeutic ImpactThere are no FDA-approved therapeutics to treat GBS, and tanruprubart is seen as a meaningful improvement in care.
Bears Say
Approval UncertaintyProof-of-concept data from the oral complement inhibitor program ANX1502 is now anticipated by YE25 instead of mid-2025.
Regulatory ChallengesRegulatory talks still ongoing with FDA around requirements for the BLA submission of tanruprubart in Guillain-Barré Syndrome.
Annexon Biosciences News
ANNX FAQ
What was Annexon Biosciences’s price range in the past 12 months?
Annexon Biosciences lowest stock price was $1.28 and its highest was $7.85 in the past 12 months.
What is Annexon Biosciences’s market cap?
Annexon Biosciences’s market cap is $350.54M.
When is Annexon Biosciences’s upcoming earnings report date?
Annexon Biosciences’s upcoming earnings report date is Nov 12, 2025 which is in 36 days.
How were Annexon Biosciences’s earnings last quarter?
Annexon Biosciences released its earnings results on Aug 14, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.366 by $0.026.
Is Annexon Biosciences overvalued?
According to Wall Street analysts Annexon Biosciences’s price is currently Undervalued.
Does Annexon Biosciences pay dividends?
Annexon Biosciences does not currently pay dividends.
What is Annexon Biosciences’s EPS estimate?
Annexon Biosciences’s EPS estimate is -0.34.
How many shares outstanding does Annexon Biosciences have?
Annexon Biosciences has 109,886,620 shares outstanding.
What happened to Annexon Biosciences’s price movement after its last earnings report?
Annexon Biosciences reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.366. Following the earnings report the stock price went up 2.521%.
Which hedge fund is a major shareholder of Annexon Biosciences?
Currently, no hedge funds are holding shares in ANNX
Annexon Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.60 (263.64% Upside)
$11.60 (263.64% Upside)
Blogger Sentiment
Bullish
ANNX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.63%
12-Months-Change
Fundamentals
Return on Equity
-66.75%
Trailing 12-Months
Asset Growth
-34.85%
Trailing 12-Months
Company Description
Annexon Biosciences
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
ANNX Stock 12 Month Forecast
Average Price Target
$11.60
▲(263.64% Upside)
Technical Analysis
Galectin Therapeutics
―
Aldeyra Therapeutics
―
Editas Medicine
―
Alector
―
Neumora Therapeutics, Inc.
―
Ownership Overview
7.61% Insiders
15.75% Mutual Funds
42.02% Other Institutional Investors
23.91% Public Companies and
Individual Investors